HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.

AbstractBACKGROUND:
Due to the limited data available in literature, the aim of this multi-centre study was to prospectively compare in thalassemia major (TM) patients the efficacy of combined deferiprone (DFP) and deferoxamine (DFO) regimen versus either DFP and DFO in monotherapy by cardiovascular magnetic resonance (CMR) over a follow up of 18 months.
METHODS:
Among the first 1135 TM patients in the MIOT (Myocardial Iron Overload in Thalassemia) network, we evaluated those who had received either combined regimen (DFO + DFP, N=51) or DFP (N=39) and DFO (N=74) monotherapies between the two CMR scans. Iron overload was measured by T2* multiecho technique. Biventricular function parameters were quantitatively evaluated by cine images.
RESULTS:
The percentage of patients that maintained a normal global heart T2* value was comparable between DFP+DFO versus both monotherapy groups. Among the patients with myocardial iron overload at baseline, the changes in the global heart T2* and in biventricular function were not significantly different in DFP+DFO compared with the DFP group. The improvement in the global heart T2* was significantly higher in the DFP+DFO than the DFO group, without a difference in biventricular function. Among the patients with hepatic iron at baseline, the decrease in liver iron concentration values was significantly higher with combination therapy than with either monotherapy group.
CONCLUSIONS:
In TM patients at the dosages used in the real world, the combined DFP+DFO regimen was more effective in removing cardiac iron than DFO, and was superior in clearing hepatic iron than either DFO or DFP monotherapy. Combined therapy did not show an additional effect on heart function over DFP.
AuthorsAlessia Pepe, Antonella Meloni, Giuseppe Rossi, Liana Cuccia, Giuseppe Domenico D'Ascola, Michele Santodirocco, Paolo Cianciulli, Vincenzo Caruso, Maria Antonietta Romeo, Aldo Filosa, Lorella Pitrolo, Maria Caterina Putti, Angelo Peluso, Saveria Campisi, Massimiliano Missere, Massimo Midiri, Letizia Gulino, Vincenzo Positano, Massimo Lombardi, Paolo Ricchi
JournalJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance (J Cardiovasc Magn Reson) Vol. 15 Pg. 1 ( 2013) ISSN: 1532-429X [Electronic] England
PMID23324167 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Iron Chelating Agents
  • Pyridones
  • deferiprone
  • Deferoxamine
Topics
  • Adult
  • Analysis of Variance
  • Cardiomyopathies (drug therapy, etiology, pathology, physiopathology)
  • Chi-Square Distribution
  • Deferoxamine (therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Iron Chelating Agents (therapeutic use)
  • Italy
  • Liver (drug effects, metabolism, pathology)
  • Magnetic Resonance Imaging, Cine
  • Male
  • Myocardium (metabolism, pathology)
  • Predictive Value of Tests
  • Prospective Studies
  • Pyridones (therapeutic use)
  • Stroke Volume (drug effects)
  • Time Factors
  • Treatment Outcome
  • Ventricular Function, Left (drug effects)
  • Ventricular Function, Right (drug effects)
  • Young Adult
  • beta-Thalassemia (complications, diagnosis, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: